Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02762877 · OUTCOME

Concordance of Genomic Alterations in EGFR Detected in Plasma Versus Tumor Tissue in Stage IV Non Squamous NSCLC Patients Who Are Newly Diagnosed or Progressing on Treatment

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer · Source last updated 2020-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Overall percent agreement (OPA)
Interval / dispersion
95% Confidence Interval
Time frame
Time between patient tumor tissue biopsy and and blood collection, up to 8 weeks

What was measured

Assess concordance of genomic alterations in EGFR detected in plasma (using the OncotypeSEQ Liquid Select assay) versus tumor tissue (assessed centrally using FoundationOne, or locally based on the patient's clinic) in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.

Analysis population: Subjects who received EGFR mutation testing on both their tissue and plasma samples.

Groups in this outcome

A - NSCLC All Comers Regardless of Genomic Alteration Status

Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A - NSCLC All Comers Regardless of Genomic Alteration Status117

Reported measurements

Source class 1
Values in Overall percent agreement (OPA) · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
A - NSCLC All Comers Regardless of Genomic Alteration Status94.0Not reported88.197.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        88.1
        upper Limit
        97.6
        value
        94.0
denoms
  1. counts
    1. group Id
      OG000
      value
      117
    units
    Participants
description
Assess concordance of genomic alterations in EGFR detected in plasma (using the OncotypeSEQ Liquid Select assay) versus tumor tissue (assessed centrally using FoundationOne, or locally based on the patient's clinic) in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)
    id
    OG000
    title
    A - NSCLC All Comers Regardless of Genomic Alteration Status
param Type
NUMBER
population Description
Subjects who received EGFR mutation testing on both their tissue and plasma samples.
reporting Status
POSTED
time Frame
Time between patient tumor tissue biopsy and and blood collection, up to 8 weeks
title
Concordance of Genomic Alterations in EGFR Detected in Plasma Versus Tumor Tissue in Stage IV Non Squamous NSCLC Patients Who Are Newly Diagnosed or Progressing on Treatment
type
PRIMARY
unit Of Measure
Overall percent agreement (OPA)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice